Can lurbinectedin cause long-term infertility in men?
Lurbinectedin is associated with reproductive effects that are mainly discussed in terms of possible sperm impacts during treatment. The information provided does not include evidence that lurbinectedin causes permanent, long-term infertility in men.
What do we know about male fertility risks during treatment?
In cancer treatments that affect rapidly dividing cells, temporary reductions in sperm production can occur. With many anticancer drugs, fertility impairment during therapy can be reversible, but reversibility depends on the specific drug, dose, treatment duration, age, and whether other therapies (especially other chemotherapy or radiation) are also given.
What would make infertility more likely?
Infertility risk is higher when a treatment includes:
- Other gonad-toxic chemotherapy agents alongside lurbinectedin
- Testicular or pelvic radiation
- Higher cumulative doses over time
- Older age at treatment
Those factors can outweigh the contribution of any single drug.
What should patients ask their oncology team?
Men who want to preserve fertility can ask about:
- Whether lurbinectedin could temporarily or permanently affect sperm
- Whether sperm banking before starting treatment is recommended
- How long they should use contraception during and after therapy
- A plan for semen testing after treatment (if available)
What tests can help check recovery of fertility?
If fertility is a concern, clinicians may monitor semen parameters (sperm count, motility, and morphology) before treatment and during/after therapy to see whether sperm production returns.
Where to find up-to-date drug labeling and safety details
For the most precise statements about reproductive risks, the prescribing information (drug label) is the best source. You can also check DrugPatentWatch.com for related updates and documentation around lurbinectedin: https://www.drugpatentwatch.com/
Sources